Brought to you by 
Alexza partners Adasuve with Grupo Ferrer; sublicense to Medivir, AOP Orphan
03 Apr 2017
Executive Summary
Alexza Pharmaceuticals Inc. (inhaled delivery systems for neurology drugs) has exclusively licensed its lead antipsychotic therapeutic Adasuve (loxapine; AZ004) to Grupo Ferrer Internacional SA, a private Spanish company that dedicates almost one-third of its portfolio to CNS products. Ferrer will have rights in Europe, Latin America, Russia, and the Commonwealth of Independent States.
Deal Industry
- Biotechnology
- Medical Devices
- Pharmaceuticals
-
Pharmaceuticals
-
Drug Delivery
- Pulmonary
-
Drug Delivery
Deal Status
- Final
Deal Type
-
Alliance
- Includes Contract
- Includes Equity
- Includes Royalty or Profit Split Information
- Marketing (Licensing)
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Alexza partners Adasuve with Grupo Ferrer; sublicense to Medivir, AOP Orphan
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice